CA2199400A1 - Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases - Google Patents

Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases

Info

Publication number
CA2199400A1
CA2199400A1 CA002199400A CA2199400A CA2199400A1 CA 2199400 A1 CA2199400 A1 CA 2199400A1 CA 002199400 A CA002199400 A CA 002199400A CA 2199400 A CA2199400 A CA 2199400A CA 2199400 A1 CA2199400 A1 CA 2199400A1
Authority
CA
Canada
Prior art keywords
blood
photodynamic therapy
immune dysfunction
treating immune
selective cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002199400A
Other languages
French (fr)
Other versions
CA2199400C (en
Inventor
Simon Leong
Agnes How-Ching Chan
David William Carey Hunt
Martin Renke
Janice North
Julia Levy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Novelion Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/309,509 external-priority patent/US5807881A/en
Application filed by Individual filed Critical Individual
Publication of CA2199400A1 publication Critical patent/CA2199400A1/en
Application granted granted Critical
Publication of CA2199400C publication Critical patent/CA2199400C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Multiple sclerosis and rheumatoid arthritis can be treated effectively using photodynamic therapy. In this protocol, a photoactive compound is administered, allowed to distribute in the affected subject, and the subject is then irradiated to activate the photoactive compound. Alternatively, the blood of a subject to be treated can be subjected to PDT extracorporeally. In the case of rheumatoid arthritis, localized treatment at the joints may also be employed.
CA002199400A 1994-09-22 1995-09-22 Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases Expired - Fee Related CA2199400C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/309,509 US5807881A (en) 1992-05-27 1994-09-22 Method for selectively reducing activated leukocyte cell population
US08/309,509 1994-09-22
PCT/CA1995/000543 WO1996009068A1 (en) 1994-09-22 1995-09-22 Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases

Publications (2)

Publication Number Publication Date
CA2199400A1 true CA2199400A1 (en) 1996-03-28
CA2199400C CA2199400C (en) 2006-02-14

Family

ID=35892305

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002199400A Expired - Fee Related CA2199400C (en) 1994-09-22 1995-09-22 Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases

Country Status (1)

Country Link
CA (1) CA2199400C (en)

Also Published As

Publication number Publication date
CA2199400C (en) 2006-02-14

Similar Documents

Publication Publication Date Title
NO971355L (en) Photodynamic Therapy in Selective Cell Inactivation in Blood and Treatment of Immune Dysfunction Diseases
GEP20002146B (en) Therapeutic Peptide Derivatives
EP0333606A3 (en) Preparation of t-cell and t-cell membrane for use in prevention and treatment of autoimmune diseases
MY113059A (en) Controlled-release dosage forms of azithromycin
PL338982A1 (en) Drug for improving duration of muscle action or for treating muscular disorders or diseases
CA2149924A1 (en) Use of phenserine to treat cognitive disorders
KR20010021630A (en)
AU693833B2 (en) Products containing G-CSF and TNF binding protein
CA2199400A1 (en) Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases
AU1601499A (en) Citicoline to treat motor neuron diseases and demyelinating diseases
AU6955396A (en) Combination therapy for advanced cancer comprising temozolomide and cisplatin
AU7373196A (en) Combination of temozolomide and alpha-ifn for the treatment of advanced cancer
WO1998025594A3 (en) Lamotrigine in the treatment and prophylaxis of migraine
RU93032381A (en) METHOD FOR TREATING CHRONIC OPISTORCHOSIS
WO2000033823A3 (en) Methods of using temozolomide in the treatment of cancers
UA30125A (en) Method of treatment of the children with rheumatoid arthritis and connective tissue diseases
WO1993022433A3 (en) Medicament for the gene-therapeutic treatment of human beings, animals and plants, especially to block virus multiplication and carcinogenes and process for producing the medicament
RU94020373A (en) Rheumatic arthritis treatment method
MX9603833A (en) Improved cancer treatment with temozolomide.
RU95106897A (en) Psoriasis treatment method
θ‘›ι€šθΏœ et al. AN APPROACH TO THE MECHANISMS OF LASER ACUPUNCTURE IN TREATMENT OF EXOPHTHALMIC HYPERTHYROIDISM
GEP19981480B (en) Method for Treating Vertebral Column
RU95109332A (en) Method of plasmaphoresis treatment of patients with chronic liver diseases and manifestations of liver disorder
RU95105085A (en) Method for acting on biological object
RU95111425A (en) METHOD FOR TREATING PSORIASIS

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed